Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
2022; Massachusetts Medical Society; Volume: 386; Issue: 26 Linguagem: Inglês
10.1056/nejmoa2202028
ISSN1533-4406
AutoresJaime Gállego Pérez‐Larraya, Marc García-Moure, Sara Labiano, Ana Patiño‐García, Jessica Dobbs, Marisol González-Huarriz, Marta Zalacain, Lucía Marrodán, Naiara Martínez-Vélez, Montse Puigdelloses, Virginia Laspidea, Itziar Astigarraga, Blanca López‐Ibor, Ofelia Cruz, Miren Oscoz Lizarbe, Sandra Hervás‐Stubbs, Gorka Alkorta‐Aranburu, Ibón Tamayo, Beatriz Tavira, Rubén Hernández-Alcoceba, Chris Jones, Gitanjali Dharmadhikari, Cristian Ruiz-Moreno, Henk G. Stunnenberg, Esther Hulleman, Jasper van der Lugt, Miguel Á. Idoate, Ricardo Díez-Valle, Inés Esparragosa Vázquez, María Villalba, Carlos de Andrea, Jorge M. Núñez‐Córdoba, Brett Ewald, Joan M. Robbins, Juàn Fueyo, Candelaria Gomez‐Manzano, Frederick F. Lang, Sonia Tejada, Marta M. Alonso,
Tópico(s)CAR-T cell therapy research
ResumoPediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been evaluated in patients with pediatric gliomas elsewhere in the brain, but data regarding oncolytic viral therapy in patients with DIPG are lacking.
Referência(s)